Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.

This review discusses the evolving understanding of frontal fibrosing alopecia as a generalized skin condition with diverse manifestations, and reports no new clinical results.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This study reviewed clinical data from 60 patients with frontal fibrosing alopecia and found increasing prevalence and generally poor response to treatment, with the cause remaining unclear.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This meta-analysis suggests a significant association between the use of facial sunscreen and moisturizer and frontal fibrosing alopecia, while finding no significant relationship with hair products or treatments.

This study suggests that TGF-alpha may function in an autocrine or juxtacrine manner rather than promoting cell proliferation during hair growth cycles in ferrets and sheep.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This abstract describes frontal fibrosing alopecia, a type of cicatricial alopecia identified in post-menopausal women, and reports no new clinical findings.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

This review discusses the enigmatic nature of frontal fibrosing alopecia and reports no clinical results; the authors stress the need for further research.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

This article reviews the development of follicular unit transplantation for hair replacement, highlighting its ability to provide natural-looking results with minimal recovery time, but results depend heavily on the skill and planning of the practitioner.

This case report describes a 46-year-old man diagnosed with frontal fibrosing alopecia, a condition primarily affecting postmenopausal women, highlighting its rare occurrence in men.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This article discusses the authors' concerns over the misinterpretation of studies linking smoking and frontal fibrosing alopecia, clarifying that neither study suggests smoking is protective against the condition.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

This study found that the film-trigger applicator system enhanced drug delivery efficiency and skin penetration of dissolving microneedles compared to traditional patch systems in both lab and animal models.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

This study identified that trichoscopy can effectively diagnose frontal fibrosing alopecia by highlighting specific scalp abnormalities in postmenopausal women.